Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ImmuCell Corporation (ICCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ICCC (1-star) is a SELL. SELL since 4 days. Profits (11.84%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.13% | Avg. Invested days 30 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.00M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 0.31 | 52 Weeks Range 3.34 - 7.60 | Updated Date 06/29/2025 |
52 Weeks Range 3.34 - 7.60 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-06-13 | When Before Market | Estimate - | Actual 0.1611 |
Profitability
Profit Margin -1% | Operating Margin (TTM) 13.85% |
Management Effectiveness
Return on Assets (TTM) 0.26% | Return on Equity (TTM) -1.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 69390310 | Price to Sales(TTM) 2.23 |
Enterprise Value 69390310 | Price to Sales(TTM) 2.23 | ||
Enterprise Value to Revenue 2.54 | Enterprise Value to EBITDA 23.58 | Shares Outstanding 9037400 | Shares Floating 6007971 |
Shares Outstanding 9037400 | Shares Floating 6007971 | ||
Percent Insiders 27.91 | Percent Institutions 18.98 |
Analyst Ratings
Rating 1 | Target Price 14 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ImmuCell Corporation
Company Overview
History and Background
ImmuCell Corporation was founded in 1982 and is based in Portland, Maine. It focuses on developing, manufacturing, and marketing products that improve animal health and productivity in the dairy and beef industries. Initially focused on research and development, ImmuCell shifted to commercialization with its lead product, First Defenseu00ae.
Core Business Areas
- First Defenseu00ae: This segment focuses on the development, manufacture, and sale of First Defenseu00ae, a line of colostrum-based products for newborn calves and lambs. These products provide immediate immunity to prevent disease and improve survival rates.
- Re-Tainu00ae: Re-Tain is a treatment for subclinical mastitis in dairy cows during lactation, providing an alternative to traditional antibiotics.
- Future Product Development: ImmuCell continues to invest in research and development to expand its product portfolio, targeting unmet needs in the animal health market.
Leadership and Structure
Michael F. Brigham serves as the President and CEO. The company has a board of directors overseeing the management team. The organizational structure includes departments for research, development, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- First Defenseu00ae: First Defenseu00ae is a line of colostrum-based products providing passive immunity to newborn calves and lambs. It's a leading product in its niche, though specific market share data is difficult to pinpoint precisely due to the fragmented nature of the animal health market. Competitors include companies offering similar colostrum-based or antibody products like Agri-Labs and Land O'Lakes.
- Re-Tainu00ae: Re-Tainu00ae is an intramammary treatment for subclinical mastitis in lactating dairy cows. It aims to reduce somatic cell count and improve milk quality. Sales of Re-Tain are growing, but still lower than First Defense. Competitors include Zoetis (DRAXXIN), Merck Animal Health (SPECTRAMAST DC).
Market Dynamics
Industry Overview
The animal health industry is growing, driven by increased demand for animal protein, heightened awareness of animal welfare, and advancements in veterinary medicine. Disease prevention and treatment in livestock are crucial for food security and economic stability.
Positioning
ImmuCell is a niche player focused on preventative and therapeutic solutions for the dairy and beef industries. Its competitive advantage lies in its specialized expertise in bovine health and its focus on colostrum-based and alternative treatment options like Re-Tain.
Total Addressable Market (TAM)
The global animal health market is estimated to be around $50 billion. ImmuCell's TAM is focused on the dairy and beef cattle sector which is smaller, estimated in the billions. ImmuCell is positioned to capture a greater portion through innovative product development and market expansion.
Upturn SWOT Analysis
Strengths
- Specialized expertise in bovine health
- Established brand reputation with First Defenseu00ae
- Innovative product development capabilities
- Strong relationships with key distributors
- Growing sales of Re-Tainu00ae
Weaknesses
- Limited product portfolio
- Small market capitalization
- Reliance on a single major product (First Defenseu00ae)
- Susceptibility to commodity price fluctuations (colostrum)
- Geographic concentration of sales
Opportunities
- Expansion into new geographic markets
- Development of new products for other livestock species
- Strategic partnerships and acquisitions
- Increased demand for antibiotic alternatives
- Growing awareness of animal welfare
Threats
- Competition from larger animal health companies
- Regulatory changes impacting product approvals
- Disease outbreaks affecting livestock populations
- Fluctuations in commodity prices (colostrum)
- Economic downturns reducing farm incomes
Competitors and Market Share
Key Competitors
- ZOETIS (ZTS)
- MERCK (MRK)
- ELANCO ANIMAL HEALTH INC (ELAN)
Competitive Landscape
ImmuCell faces intense competition from larger, more diversified animal health companies. Its advantages include its specialized expertise and established brand in colostrum products. Disadvantages include its limited product portfolio and smaller market capitalization.
Growth Trajectory and Initiatives
Historical Growth: ImmuCell's historical growth has been driven primarily by First Defenseu00ae sales. Re-Tainu00ae is showing promising growth potential.
Future Projections: Future growth depends on the successful commercialization of new products and expansion into new markets. Analyst estimates suggest continued revenue growth, but projections vary.
Recent Initiatives: Recent initiatives include expanding the Re-Tainu00ae sales force, investing in research and development for new mastitis treatments, and exploring partnerships for international distribution.
Summary
ImmuCell is a niche animal health company specializing in bovine health, particularly through its First Defense product line. Re-Tain offers an alternative treatment for mastitis, and they also keep a continued focus on new product development. Strengths include specialized expertise and a established brand in colostrum products. ImmuCell needs to manage competition from larger animal health firms while expanding their product portfolio to achieve more sustainable growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and is subject to change. Market share data may be estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ImmuCell Corporation
Exchange NASDAQ | Headquaters Portland, ME, United States | ||
IPO Launch date 1987-04-30 | President, CEO, Treasurer, Secretary & Director Mr. Michael F. Brigham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 67 | Website https://immucell.com |
Full time employees 67 | Website https://immucell.com | ||
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.